Explore ›
Finding
Finding
decline
Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8% vs 59.8%), the largest absolute disparity gap at 13.0 percentage points.
| Effect size | adjusted OR 0.66 |
| CI | 95% CI = 0.55-0.79 |
| Comparator | Non-IDD patients with HF in the same commercially insured database (n=236,638) |
| Effect summary | decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79 |
| Effect modifiers | [{"modifier": "IDD subtype (Down syndrome)", "interaction_p": "", "direction": "amplifies", "stratum_details": "Down syndrome vs autism spectrum disorder: adjusted OR 0.34, 95% CI 0.14-0.82 for beta-blocker use in HF", "plain_language": "Patients with Down syndrome had the lowest beta-blocker prescribing rates for heart failure of any IDD subtype", "annotation_notes": "Subgroup analysis within IDD patients, with autism spectrum disorder as reference group"}] |
Connected entities
Interventions
Outcomes
Source
PMC8009695
Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database